# Trial to Evaluate Safety, Tolerability, Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis

> **NCT04093895** · PHASE2 · COMPLETED · sponsor: **Geistlich Pharma AG** · enrollment: 12 (actual)

## Conditions studied

- Periodontitis

## Interventions

- **DRUG:** PerioSept(r)

## Key facts

- **NCT ID:** NCT04093895
- **Lead sponsor:** Geistlich Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-26
- **Primary completion:** 2020-06-10
- **Final completion:** 2020-09-25
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04093895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04093895, "Trial to Evaluate Safety, Tolerability, Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04093895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*